Skip to content

Phase I trial: Celerion code CA33748

Phase I trial: Celerion code CA33748

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN68610794
Enrollment
189
Registered
2025-01-13
Start date
2022-01-10
Completion date
Unknown
Last updated
2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers Not Applicable

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Sponsors

Alkem (India)
Lead Sponsor
Enzene BioSciences Ltd.
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion criteria

Exclusion criteria: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Design outcomes

Primary

MeasureTime frame
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Secondary

MeasureTime frame
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Countries

Bulgaria, England, Northern Ireland, Poland, United Kingdom

Contacts

Public ContactVinayaka Shahavi
vinayaka.shahavi@alkem.com+9122 39829999

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026